Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + pomalidomide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Durvalumab + pomalidomide is a combination therapy studied in patients with relapsed/refractory multiple myeloma. **Durvalumab** is a monoclonal antibody that inhibits **programmed death ligand 1 (PD-L1)**, thereby blocking an immune checkpoint pathway and promoting antitumor immune responses. **Pomalidomide** is an immunomodulatory agent (IMiD) that enhances immune system activity against myeloma via multiple mechanisms, including stimulating T-cells and natural killer (NK) cells and inhibiting tumor-supportive microenvironment signals. This combination was investigated to harness additive or synergistic immunomodulation, with clinical studies showing modulation of immune cell subsets and gene expression profiles in the disease microenvironment[1][2].
- Other names
- MEDI4736 + pomalidomide
02
Targets
CRBN (Cereblon)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + pomalidomide.